| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 15 | -474,431 | 100% | $86.90 | -$41,229,012 |
| Net | -15 | -474,431 | -100% | -$41,229,012 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| MERIDIAN VENTURE PARTNERS II LP | 10%+ Owner | $102,678,978 | 16 Aug 2023 | ||
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS, Director | $43,712,127 | -$17,914,322 | -29% | 11 Feb 2026 |
| Nikhil Lalwani | PRESIDENT & CEO, Director | $27,739,284 | -$4,894,573 | -15% | 12 Feb 2026 |
| Chad Gassert | Svp Corp. Dev. & Strategy | $18,476,015 | -$3,051,835 | -14% | 12 Feb 2026 |
| STEPHEN P. CAREY | Svp & Cfo | $13,157,620 | -$4,303,500 | -25% | 12 Feb 2026 |
| James G. Marken | Svp Ops & Prod Dev | $7,977,023 | 07 Jun 2024 | ||
| Christopher Mutz | Head Of Rare Disease | $6,975,009 | -$780,100 | -10% | 20 Feb 2026 |
| Ori Gutwerg | Svp, Generics | $6,302,425 | -$884,161 | -12% | 12 Feb 2026 |
| Patrick D. Walsh | Director | $5,369,171 | -$1,552,354 | -22% | 13 Nov 2025 |
| Meredith W. Cook | Sr. Vp, General Counsel & Sec. | $5,225,668 | -$387,649 | -6.9% | 12 Feb 2026 |
| Krista Davis | Svp, Chief Hr Officer | $4,106,036 | -$574,452 | -12% | 19 Feb 2026 |
| THOMAS HAUGHEY | Director | $3,138,249 | -$1,661,972 | -35% | 12 Aug 2025 |
| Thomas Andrew Rowland | Svp, Head Established Brands | $2,948,112 | -$426,407 | -13% | 12 Feb 2026 |
| Robert E. Brown Jr. | Director | $2,766,745 | 27 Apr 2022 | ||
| DAVID NASH | Director | $2,176,383 | 23 May 2023 | ||
| Antonio R. Pera | Director | $2,151,340 | -$1,178,729 | -35% | 03 Sep 2025 |
| Jeanne Thoma | Director | $2,080,002 | -$1,920,370 | -48% | 18 Aug 2025 |
| RENEE P. TANNENBAUM | Director | $2,041,490 | -$146,070 | -6.7% | 05 Dec 2025 |
| Matthew J. Leonard | Director | $622,015 | -$840,723 | -57% | 25 Aug 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|